Overview

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
OSI Pharmaceuticals